Official Title
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Brief Title
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Protocol ID
NCT04312906
Lead Sponsor
Centre for Infectious Disease Research in Zambia
Brief Summary
This study aims to address the paucity of accurate incidence data of diarrheal diseases
associated with Shigella in Zambia and Burkina Faso. Given the limited feasibility of the
current complex diagnostic methods used to detect Shigella in endemic and developing
countries due to the costs, the none availability of reagents and a requirement of
expensive and complex machinery, we suggest to use a rapide, easy-to-use, cost-effective,
and robust Polymerase Chain Reaction (PCR) based rapid tool, the Loop-mediated isothermal
amplification (LAMP) based diagnostic assay (ES-RLDT). This baseline study will enable us
to generate an accurate estimate of Shigella incidence so as to inform future trials'
designs of an oral vaccine development (ShigOraVax) in Burkina Faso and Zambia.
This project is part of the EDCTP2 programme supported by the European Union under grant
agreement "No RIA2018V-2308
Detailed Description
This is an observational, cohort study to determine the incidence of Shigella in children
under 5 years in Zambia and Burkina Faso.
We will first identify the population at risk i.e children that will form the cohort of
children to be followed up in the study. In Zambia, this will be done through a household
census that will be conducted to identify children under 5 years in the catchment areas
served by the selected health facility. In Burkina Faso, the study will be conducted in
the Ouagadougou Health and Demographic Surveillance System (OHDSS) catchment area.
Children under five years old will be randomly selected from the OHDSS database. The
heads of households or guardians of the randomly selected children will be approached for
the informed consenting process to enrol into the cohort study.
We will then follow up these children using active and passive surveillance systems
follow for the duration of the study. During passive follow-up, a surveillance system
will be set up at the selected health facilities serving the catchment populations.
Parents/guardians of enrolled children will be asked to take their child to designated
health facilities once they develop an episode of diarrhoea. At presentation, a clinical
evaluation will be performed on the child and the data recorded. A stool sample/rectal
swab will then be collected. Once a stool sample is tested positive for Shigella, the
participant will be actively followed up and monitored on days 3, 5, 7 and 9 to inquire
about the disease outcome and to collect blood and stool samples.
Active follow-ups will include a combined home and clinic visits. The parents or
guardians of participants enrolled in the study will be contacted through phone calls
and/or home visits by trained study staff every month to collect information on the child
health status. They will enquire on whether the child had an episode of diarrhoea and
fever in the preceding four weeks, the use of healthcare services for the diarrhoea
episode and any treatment received for the diarrhoea and fever. If an episode of
diarrhoea is detected during any of the active visits, the parents/guardians will be
encouraged to take the child to the clinic for appropriate management. The child will
then go through the passive surveillance procedures.
MSD cases will be defined as a three or more loose stools or at least one bloody/mucoid
stool within a 24 hour period (WHO, 2005). A diarrhoea episode will be defined as new if
the diarrhea definition is met after seven days free of diarrhoea or dysentery. A
Shigella case will be defined as any loose stool with LAMP confirmed Shigella.
In Ndola, the burden of shigella disease will be determined in under five children
presenting with moderate to severe diarrhea and admitted to Arthur Davison children's
hospital in Ndola.
Study Period
-
Enrollment Count
1,334 participants
Eligibility Criteria
Inclusion Criteria:
- Children who are under five years, are resident in the catchment areas of
participating health facilities and whose parents or guardians have no anticipated
plan to leave the area for the next 12 months;
- Willing to submit child biological samples for testing and/or storage;
- Parent or guardian providing written informed consenting to the study.
Exclusion Criteria:
- Any child born after the Census has taken place(Zambia) or whose household was not
randomly selected from the database (Burkina Faso)
- Current participation in a research with the use of any drug or vaccine.
- Parent or guardian unwilling to provide consent
- Any confirmed or suspected immunosuppressive or immuniodeficiency condition based on
medical history and physical examination (No testing will be done for HIV)
- A family history of congenital or hereditary immunodeficiency
- Major congenital defects
- Immunosuppresive therapy within 3 months prior to recruitment
Filters
Diarrhea
Diarrhea Infectious
COMPLETED
CHILD